Evolution of the Average Target: Alvotech

Evolution of the Target Price: Alvotech

Changes in Analyst Recommendations: Alvotech

c35ac42b.R8OzNQAvcflieYqTVTPyL3oqSFaQGzH5tDTp_aWesuA.dJzjQ21mJ5sBLc_WClW0dzMTAifFRESUhVbcp9Op_9AsotlYR2QevScL6Q~a33bf67da57d0ada53a3228f91aa68e8
16/09 Alvotech Shares Rise After Double Upgrade From Barclays MT
16/09 Barclays Upgrades Alvotech to Overweight From Underweight, Adjusts PT to $8 From $4 MT
24/08 Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says MT
24/08 BofA Securities Initiates Alvotech at Buy With $7 Price Target MT
24/03 UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating MT
24/03 Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating MT
22/12 Stockholm Bullets - Viscaria Soars on Buy Recommendation FW
18/11 UBS Adjusts Alvotech Price Target to $10 From $13, Maintains Buy Rating MT
05/11 Alvotech Shares Fall After Deutsche Bank Downgrade MT
04/11 Deutsche Bank Downgrades Alvotech to Hold From Buy, Adjusts Price Target to $8 From $14 MT
04/11 Deutsche Bank Downgrades Alvotech to Hold From Buy, Cuts Price Target to $8 From $14 MT
03/11 Alvotech Shares Slide on FDA Demands for Application for Arthritis Drug Biosimilar DJ
03/11 Top Premarket Decliners MT
03/11 Alvotech's Potential Arthritis Biosimilar Receives FDA Complete Response Letter; Shares Down Pre-Bell MT
03/11 Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 CI
15/25/15 Alvotech Shares Rise After Morgan Stanley Upgrade MT
14/25/14 Morgan Stanley Upgrades Alvotech to Overweight From Equalweight, Price Target is $14 MT
23/25/23 Alvotech Set to Benefit from Opportunities in Biosimilars Market, Deutsche Bank Says MT
23/25/23 Deutsche Bank Upgrades Alvotech to Buy From Hold, Price Target is $14 MT
21/25/21 UBS Says Alvotech Set for H2 Growth on Pipeline Launches, Private Label Deal MT
18/25/18 UBS Adjusts Price Target on Alvotech to $14 From $16, Maintains Buy Rating MT
25/24/25 Barclays Adjusts Price Target on Alvotech to $18 From $22, Maintains Overweight Rating MT
24/24/24 Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating MT
22/24/22 Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating MT
29/24/29 Barclays Upgrades Alvotech to Overweight From Equalweight, Raises Price Target to $17 From $10 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+15.65%
+20.73%
+1.06%
+20.23%
+27.05%
+50.95%
-6.25%
-7.05%
+35.3%
-16.64%
Average +14.10%
Weighted average by Cap. +17.11%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.880USD
Average target price
6.800USD
Spread / Average Target
+15.65%
High Price Target
9.000USD
Spread / Highest target
+53.06%
Low Price Target
4.000USD
Spread / Lowest Target
-31.97%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB